Geva Eli, Lerner-Geva Liat, Burke Michael, Vardinon Nurit, Lessing Joseph B, Amit Ami
The IVF Unit, Department of Obstetrics and Gynecology, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Am J Reprod Immunol. 2004 May;51(5):336-40. doi: 10.1111/j.1600-0897.2004.00165.x.
Systemic lupus erythematosous (SLE) is a chronic disease with a broad spectrum of clinical and immunological manifestations, therefore, this condition may be frequently misdiagnosed. The current study was conducted to determine the prevalence of undiagnosed SLE among a cohort of infertile women.
Screening was performed using sequential (two stage) testing, which included a self-completed questionnaire followed by an antinuclear antibody (ANA) test. The Liang screening questionnaire was distributed to 143 consecutive infertile patients, aged 24-42 years (mean, 33.6 +/- 4.7 years), who were receiving in-vitro fertilization (IVF) treatment. Patients who completed the questionnaire with three or more positive answers, were sent for ANA testing; those who tested positive (>or=1:40) were referred to the Clinical Immunology Unit for anti-double-stranded DNA (dsDNA) antibody test and clinical assessment.
A total of 136 women (95.1%) completed the questionnaire. Thirteen patients (9.6%) answered yes to three or more questions. Of these, five patients (3.7%) were ANA-positive and two (1.5%) had undiagnosed SLE.
A 1.5% prevalence of undiagnosed SLE was found in our cohort of infertile women. Additional investigations should be performed as to the role of SLE screening in infertile female population; a high-risk group with regard to ovulation induction treatments.
系统性红斑狼疮（SLE）是一种具有广泛临床和免疫表现的慢性疾病，因此这种病症可能经常被误诊。本研究旨在确定一组不孕女性中未被诊断出的SLE的患病率。
采用序贯（两阶段）检测进行筛查，包括一份自我填写的问卷，随后进行抗核抗体（ANA）检测。将梁氏筛查问卷分发给143名连续接受体外受精（IVF）治疗的24至42岁（平均33.6 +/- 4.7岁）的不孕患者。完成问卷且有三个或更多肯定回答的患者被送去进行ANA检测；检测呈阳性（>或=1:40）的患者被转至临床免疫学科室进行抗双链DNA（dsDNA）抗体检测和临床评估。
共有136名女性（95.1%）完成了问卷。13名患者（9.6%）对三个或更多问题回答“是”。其中，5名患者（3.7%）ANA呈阳性，2名（1.5%）患有未被诊断出的SLE。
在我们的不孕女性队列中发现未被诊断出的SLE的患病率为1.5%。应进一步研究SLE筛查在不孕女性群体中的作用；这是一个在促排卵治疗方面的高危群体。
